Type I Diabetes I: Introduction

Type 1 diabetes results from autoimmune destruction of insulin-producing pancreatic beta cells. The immune system mistakenly targets and destroys these cells, preventing insulin production. This autoimmune process develops from a combination of genetic and environmental factors, leading to gradual beta-cell loss in genetically susceptible individuals.

Without functional beta cells, the body cannot produce insulin, which is essential for glucose uptake by cells. This impaired glucose uptake causes chronic hyperglycemia, or persistently elevated blood glucose levels. The resulting high blood sugar requires lifelong insulin therapy to maintain normal glucose metabolism.

Specific genes in the human leukocyte antigen (HLA) complex, particularly HLA-DR3 and HLA-DR4, are strongly associated with increased type 1 diabetes risk. Having a first-degree relative with the condition also raises the likelihood of developing it. These genetic variants shape antigen presentation and may promote loss of immune tolerance to beta-cell antigens.

Autoantibodies directed against key beta-cell antigens, including insulin, glutamic acid decarboxylase 65 (GAD65), and tyrosine phosphatase IA-2, accompany the autoimmune response in type 1 diabetes. These autoantibodies serve as important markers of disease risk and are frequently detectable long before symptoms appear, helping identify individuals at risk.

Type 1 diabetes mellitus can develop at any age but is most frequently diagnosed in children, adolescents, and young adults. Although the autoimmune destruction of beta cells develops gradually and often remains clinically silent, the condition typically manifests during these earlier life stages.

Environmental influences modify disease risk in genetically susceptible individuals. Viral infections, early-life exposures, and other environmental triggers may initiate or accelerate autoimmunity by altering beta-cell antigens or stimulating immune activation. Together with genetic predisposition, these environmental factors culminate in progressive beta-cell destruction.

Autoreactive T lymphocytes play a central role in type 1 diabetes, infiltrating the pancreatic islets and initiating cell-mediated cytotoxicity against beta cells. This immune-mediated attack develops gradually, often remaining clinically silent until most beta-cell mass is lost and insulin deficiency becomes apparent.